Dendreon —"There’s one catalyst left for Dendreon this year—that’s getting FDA approval…I believe that the probability for approval is about 90 percent,” he said. “That’s a reasonable catalyst for the stock this year to push up another 20 percent or so and that should come May 1.”
Acorda Therapeutics —“The Street estimates are still a little bit low and I think they’re going to beat numbers over the next year or so.”
Schoenebaum recommended investors who are looking into the biotech sector to consider investing through ETFs or actively managed mutual funds.
______________________________ More Market Views:
______________________________ CNBC Data Pages:
______________________________Page 2 of 3 | Prev Page | Next Page